No Data
No Data
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Morgan Stanley Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $311
Morgan Stanley analyst Terence Flynn maintains $Biogen(BIIB.US)$ with a buy rating, and adjusts the target price from $331 to $311.According to TipRanks data, the analyst has a success rate of 64.8%
Morgan Stanley Adjusts Price Target on Biogen to $311 From $331
Biogen (BIIB) has an average rating of outperform and price targets ranging from $200 to $350, according to analysts by Capital IQ.Price: 231.00, Change: -1.75, Percent Change: -0.75
Biogen, Eisai Say Alzheimer's Drug Leqembi Secures Regulatory Approval in Hong Kong
Biogen (BIIB) and Eisai said Thursday that the Alzheimer's disease drug Leqembi has been approved by Hong Kong's Department of Health.The approval was based on a late-stage trial that met its
Barclays Remains a Hold on Biogen (BIIB)
RBC Cuts Price Target on Biogen to $303 From $317, Keeps Outperform Rating
Biogen (BIIB) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $200 to $350.Price: 228.20, Change: +0.13, Percent Change: +0.06